Loading
KLN-1010 is an experimental in vivo CAR-T gene therapy from Kelonia Therapeutics, in phase 1 trials for relapsed and refractory multiple myeloma.
KLN-1010 is an in vivo CAR-T gene therapy (lentiviral-based iGPS particles, one-time intravenous dose) from Kelonia Therapeutics, with Eli Lilly and Company as acquirer. A one-time intravenous gene therapy whose engineered lentiviral particles enter T cells inside the body so that the patient's own cells make CAR-T cells against BCMA (B cell maturation antigen), as the registry's study title states; no cell collection or manufacturing is needed. Its furthest stage is phase 1, for relapsed and refractory multiple myeloma. ClinicalTrials.gov registers it in one study linked below. Phase 1 inMMyCAR open and enrolling (NCT07075185). Eli Lilly agreed to acquire Kelonia (announced 20 April 2026; up to $7.00 billion); site now says 'A wholly owned subsidiary of Eli Lilly and Company'. Whether it works in people has not been established unless a trial below reports it.
A one-time intravenous gene therapy whose engineered lentiviral particles enter T cells inside the body so that the patient's own cells make CAR-T cells against BCMA (B cell maturation antigen), as the registry's study title states; no cell collection or manufacturing is needed. Connects to BCMA.
1.KLN-1010 slips into a pocket on BCMA.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"KLN-1010" OR ABSTRACT:"KLN-1010") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KLN-1010, not a curated reading list.
Shares BCMA, Relapsed or refractory multiple myeloma and the tag pipeline.
Shares BCMA, Relapsed or refractory multiple myeloma and the tag pipeline.
Shares BCMA, Relapsed or refractory multiple myeloma and the tag pipeline.
Shares BCMA, Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Shares BCMA and the tag pipeline.
Shares Relapsed or refractory multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/